On Friday, Tesla Motors Inc (NASDAQ:TSLA)’s shares declined -0.29% to $250.69.
Tesla Motors Inc (TSLA) shareholder meeting held Tuesday afternoon.
On the meeting agenda, besides the re-election of two board members and affirming PricewaterhouseCoopers as Tesla’s accounting firm, were two items from environmentalist shareholders. In a form now filed with the Securities and Exchange Commission, Tesla says that the director and PwC items passed but the two environmentalist proposals did not.
The shareholder proposals, by a Texas couple, asked that Tesla curb use of animal-sourced interiors and offer faux leather alternatives.
Tesla doesn’t offer a no leather interior and had recommended a “no” vote, with the board noting that achieving the company’s mission “requires that we prioritize our efforts.”
“I found out my husband had to go through extreme measures to get an entirely vegan Tesla,” shareholder Elizabeth Farrell Peters said at the event, of the Model S she got as an anniversary gift.
Tesla stock touched a nearly seven-month high Monday but slipped 2.1% Wednesday. It is up 38% from a 13-month low in March and is forming a cup base with a buy point of 291.52.
The company gets a Composite Rating from IBD of 66 out of a possible 99 — not high but improving in recent months.
Tesla Motors, Inc. designs, develops, manufactures, and sells electric vehicles, electric vehicle powertrain components, and stationary energy storage systems in the United States, China, Norway, and internationally. It also provides development services to develop electric vehicle powertrain components and systems for other automotive manufacturers.
Hershey Co (NYSE:HSY)’s shares gained 0.31% to $91.04.
Hershey Co (HSY) declared that Humberto (Bert) P. Alfonso, 57, President, International, intends to retire from the company by the end of June. The company is working with Alfonso to ensure a seamless transition and anticipates to declare its succession plan at the end of the month.
The Hershey Company manufactures, imports, markets, distributes, and sells confectionery products. The company operates through two segments, North America; and International and Other. It offers chocolate and sugar confectionery products; pantry items, such as baking ingredients, toppings, sundae syrups, and beverages; snack items, counting spreads; and gum and mint refreshment products comprising chewing gums and bubble gums.
At the end of Friday’s trade, American Tower Corp (NYSE:AMT)‘s shares dipped -0.24% to $93.20.
American Tower Corp (AMT) declared that its board of directors has declared its quarterly cash distribution of $0.44 per share on shares of the Company’s common stock. The distribution is payable on July 16, 2015 to such stockholders of record at the close of business on June 17, 2015.
American Tower Corporation is a real estate investment trust. It invests in the real estate markets across the globe. The firm engages in leasing of space on multi-tenant communications sites to wireless service providers, radio and television broadcast companies, wireless data and data providers, government agencies and municipalities and tenants in a number of other industries. American Tower Corporation was founded in 1995 and is headquartered in Boston, Massachusetts.
MEI Pharma Inc (NASDAQ:MEIP), ended its Friday’s trading session with -4.04% loss, and closed at $1.90.
MEI Pharma Inc (MEIP) an oncology company focused on the clinical development of novel therapies for cancer, declared updated results from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza®) in elderly patients with newly diagnosed acute myeloid leukemia (AML). Data from 50 patients treated at 15 centers are being presented at the European Hematology Association (EHA) Annual Congress in Vienna. A copy of the poster, entitled “Updated Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia,” is now accessible at www.meipharma.com.
MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally accessible histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
